☆ 4.5 Letter

Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study

CLINICAL AND EXPERIMENTAL ALLERGY (2023)

Get Full Text
Add to Collection

Journal

CLINICAL AND EXPERIMENTAL ALLERGY
Volume -, Issue -, Pages -

Publisher

WILEY
DOI: 10.1111/cea.14436

Keywords

biologic agents; eosinophils; mepolizumab; omalizumab; real world; severe asthma; switching

Categories

Allergy Immunology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.